MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Mayo Clinic
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Roswell Park Cancer Institute
Immatics US, Inc.
Acepodia Biotech, Inc.
University Health Network, Toronto
Mayo Clinic
BioEclipse Therapeutics
HRYZ Biotech Co.
Gilead Sciences
Leap Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Fate Therapeutics
Corregene Biotechnology Co., Ltd
MaxCyte, Inc.
Mie University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Abramson Cancer Center at Penn Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mie University
Masonic Cancer Center, University of Minnesota
Herlev Hospital
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Shenzhen Second People's Hospital
City of Hope Medical Center
University of Washington
City of Hope Medical Center
Eisai Inc.
Cancer Research UK